On Tuesday, Leerink Partners made an adjustment to Regeneron Pharmaceuticals' (NASDAQ:REGN) stock, reducing the price target from $880 to $762 while maintaining a Market Perform rating.

Leerink Partners downgraded while Truist defended Regeneron (NASDAQ:REGN) after a judge denied the company’s motion for a preliminary injunction against Amgen (NASDAQ:AMGN) biosimilar for its ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an outperform rating in a research report released on Wednesday ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over the past six months, creating an opportunity to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Outperform to Market Perform. There are 2,433 funds or ...

Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic ...

Leerink cuts Regeneron stock price target to $762 from $880 Open in App ...